ARAina Westrheim Ravna

Aina Westrheim Ravna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aina Westrheim Ravna has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular modeling study of the testosterone metabolizing enzyme UDP-glucuronosyltransferase 2B17

    by Ingmar Trane, Georg Sager, Erik Sveberg Dietrichs, Aina Westrheim Ravna


  • Molecular Modeling and Docking Studies of the Oxytocin Receptor

    by Gloria Antobreh, Istvan Enyedy, Aina Westrheim Ravna

    Aim: Low oxytocin (OT) level is involved in a number of psychiatric diseases, indicating that OT could be used to aid treating these disorders. OT itself is unable to cross the blood–brain barrier, and development of new small nonpeptide drugs targeting the OT receptor (OXTR) may be beneficial for treating mental disorders. Results & methodology: Three OXTR models were constructed based on crystallized homologous proteins (Protein Data Bank [PDB]: 2Y00, PDB: 4BVN and PDB: 4LDE). The abilities of the models to discriminate between true binders and decoys were analyzed using receiver operating characteristics curves, and the 4LDE-based model gave the best result. Conclusion: The present study demonstrates that the 4LDE-based model may be suitable as a tool for the development of novel drugs targeting OXTR.


  • Sukkeravhengighet

    by Aina Westrheim Ravna

    Den globale økningen i fedme har i det siste fått forskere til å sammenligne sukkerholdig mat med vanedannende stoffer som kokain. Forskere har brukt de samme modellene som ble utviklet for å studere rusavhengighet hos rotter til å teste rotters avhengighet av sukker, og studier har vist at rusmidler og sukker stimulerer mange av de samme nevrale systemer i hjernen. Man har blant annet sett at rotter som er vedlikeholdt på periodevis sukkertilgang og deretter tvunget til å avstå fra sukker, viser senere økt inntak av 9 % alkohol, noe som tyder på at periodevis tilgang til sukker kan være en inngangsport til alkoholbruk. Sukker og sødme kan indusere belønning og «craving» hos mennesker som er svært likt det som fremkalles av vanedannende legemidler, og studier som dette indikerer at sukker kan være vanedannende. The global increase in obesity has lately gotten researchers to compare sugary foods with addictive drugs like cocaine. Researchers have used the same models that were developed for studying addiction in rats to test for signs of addiction to sugar in rats, and studies have shown that drugs and sugar stimulates many of the same neural systems in the brain. It has also been seen that rats maintained on intermittent sugar access and then forced to abstain from sugar have a 9% increased consumption of 9% alcohol, suggesting that intermittent access to sugar may be a gateway to alcohol use. Sugar and sweetness can induce reward and «craving» in humans that is very similar to what is induced by addictive drugs, and studies like this indicate that sugar can be addictive.

  • Synthesis, biological evaluation and molecular modeling studies of the PPARβ/δ antagonist CC618

    by Åsmund Kaupang, Steinar Martin Paulsen, Calin C. Steindal, Aina W. Ravna, Ingebrigt Sylte, Trine G. Halvorsen, G. Hege Thoresen, Trond Vidar Hansen


  • Open Access

    Comparative Molecular Dynamics Simulations of Mitogen-Activated Protein Kinase-Activated Protein Kinase 5

    by Inger Lindin, Yimingjiang Wuxiuer, Aina Westrheim Ravna, Ugo Moens, Ingebrigt Sylte

    The mitogen-activated protein kinase-activated protein kinase MK5 is a substrate of the mitogen-activated protein kinases p38, ERK3 and ERK4. Cell culture and animal studies have demonstrated that MK5 is involved in tumour suppression and promotion, embryogenesis, anxiety, cell motility and cell cycle regulation. In the present study, homology models of MK5 were used for molecular dynamics (MD) simulations of: (1) MK5 alone; (2) MK5 in complex with an inhibitor; and (3) MK5 in complex with the interaction partner p38α. The calculations showed that the inhibitor occupied the active site and disrupted the intramolecular network of amino acids. However, intramolecular interactions consistent with an inactive protein kinase fold were not formed. MD with p38α showed that not only the p38 docking region, but also amino acids in the activation segment, αH helix, P-loop, regulatory phosphorylation region and the C-terminal of MK5 may be involved in forming a very stable MK5-p38α complex, and that p38α binding decreases the residual fluctuation of the MK5 model. Electrostatic Potential Surface (EPS) calculations of MK5 and p38α showed that electrostatic interactions are important for recognition and binding.


  • Open Access

    Identification of Novel Serotonin Transporter Compounds by Virtual Screening

    by Mari Gabrielsen, Rafał Kurczab, Agata Siwek, Małgorzata Wolak, Aina W. Ravna, Kurt Kristiansen, Irina Kufareva, Ruben Abagyan, Gabriel Nowak, Zdzisław Chilmonczyk, et al.

    The serotonin (5-hydroxytryptamine, 5-HT) transporter (SERT) plays an essential role in the termination of serotonergic neurotransmission by removing 5-HT from the synaptic cleft into the presynaptic neuron. It is also of pharmacological importance being targeted by antidepressants and psychostimulant drugs. Here, five commercial databases containing approximately 3.24 million drug-like compounds have been screened using a combination of two-dimensional (2D) fingerprint-based and three-dimensional (3D) pharmacophore-based screening and flexible docking into multiple conformations of the binding pocket detected in an outward-open SERT homology model. Following virtual screening (VS), selected compounds were evaluated using in vitro screening and full binding assays and an in silico hit-to-lead (H2L) screening was performed to obtain analogues of the identified compounds. Using this multistep VS/H2L approach, 74 active compounds, 46 of which had Ki values of ≤1000 nM, belonging to 16 structural classes, have been identified, and multiple compounds share no structural resemblance with known SERT binders.


  • Open Access

    Homology modeling and ligand docking of Mitogen-activated protein kinase-activated protein kinase 5 (MK5)

    by Inger Lindin, Yimingjiang Wuxiuer, Irina Kufareva, Ruben Abagyan, Ugo Moens, Ingebrigt Sylte, Aina Westrheim Ravna

    Mitogen-activated protein kinase-activated protein kinase 5 (MK5) is involved in one of the major signaling pathways in cells, the mitogen-activated protein kinase pathway. MK5 was discovered in 1998 by the groups of Houng Ni and Ligou New, and was found to be highly conserved throughout the vertebrates. Studies, both in vivo and in vitro, have shown that it is implicated in tumor suppression as well as tumor promotion, embryogenesis, anxiety, locomotion, cell motility and cell cycle regulation.


  • Open Access

    Synthesis, Antidepressant Evaluation and Docking Studies of Long‐Chain Alkylnitroquipazines as Serotonin Transporter Inhibitors

    by Mari Gabrielsen, Karol Wołosewicz, Anna Zawadzka, Jerzy Kossakowski, Gabriel Nowak, Małgorzata Wolak, Katarzyna Stachowicz, Agata Siwek, Aina W. Ravna, Irina Kufareva, et al.

    Twelve alkyl analogues (1–12) of the high‐affinity serotonin transporter (SERT) inhibitor 6‐nitroquipazine (6‐NQ) were synthesized and studied using in vitro radioligand competition binding assays to determine their binding affinity (Ki). The putative antidepressant activity of five of the binders with the highest SERT binding affinities was studied by the forced swim and locomotor activity mouse tests. The three‐dimensional (3D) structures of 8 and 9 were determined using NOE NMR technique. Flexible docking of the compounds was undertaken to illustrate the binding of the compounds in the SERT model. Our results showed that several of the 6‐NQ analogues are high‐affinity SERT inhibitors and indicated that the octyl (8), decyl (10) and dodecyl (12) 6‐NQ analogues exhibit moderate antidepressant activity.


  • Open Access

    Novel cGMP Efflux Inhibitors Identified by Virtual Ligand Screening (VLS) and Confirmed by Experimental Studies

    by Georg Sager, Elin Ø. Ørvoll, Roy A. Lysaa, Irina Kufareva, Ruben Abagyan, Aina W. Ravna

    Elevated intracellular levels of cyclic guanosine monophosphate (cGMP) may induce apoptosis, and at least some cancer cells seem to escape this effect by increased efflux of cGMP, as clinical studies have shown that extracellular cGMP levels are elevated in various types of cancer. The human ATP binding cassette (ABC) transporter ABCC5 transports cGMP out of cells, and inhibition of ABCC5 may have cytotoxic effects. Sildenafil inhibits cGMP efflux by binding to ABCC5, and in order to search for potential novel ABCC5 inhibitors, we have identified sildenafil derivates using structural and computational guidance and tested them for the cGMP efflux effect. Eleven compounds from virtual ligand screening (VLS) were tested in vitro, using inside-out vesicles (IOV), for inhibition of cGMP efflux. Seven of 11 compounds predicted by VLS to bind to ABCC5 were more potent than sildenafil, and the two most potent showed Ki of 50–100 nM.